A National Cancer Institute-designated Comprehensive Cancer facility, the Norris Comprehensive Cancer Center at the University of Southern California is a leader in both patient care and cancer research, offering the expertise of the scientists and physicians at USC’s Keck School of Medicine combined with the latest cutting-edge technology available to aid in the diagnosis, treatment and prevention of all types of cancer, like mesothelioma.
If qualified, cancer patients at Norris are offered participation in any number of clinical trials that are being conducted at the facility at any given time. The hospital’s teams of experts can determine whether or not their patients are eligible for consideration for these studies, which test new drugs (like Carboplatin, Gemcitabine and Alimta®) and treatments for cancer. Clinical trials offered at USC/Norris Comprehensive Cancer Center are due to being awarded numerous grants, totalling more than $85 million.
Additionally, the researchers at Norris are divided into five thematic programs, which allow them to quickly bring their findings to the patients at the facility. These programs include molecular genetics, epigenetics and regulation, tumor microenvironment, cancer epidemiology and cancer control research.
- Cancer epidemiology
- Clinical trials
- Clinical oncology
- Tumor microenvironment
- National Cancer Institute Designated Comprehensive Cancer Center
Mesothelioma Clinical Trials at University of Southern California (USC)
The following clinical trials are in progress or actively recruiting participants at University of Southern California (USC):
Conditions: Carcinoma, Carcinoma, Squamous Cell, Adenocarcinoma, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Breast Neoplasms, Cholangiocarcinoma, Nasopharyngeal Carcinoma, Carcinoma, Basal Cell, Gastrointestinal Stromal Tumors, Carcinoid Tumor, Carcinoma, Transitional Cell, Carcinoma, Adenoid Cystic, Teratoma, Adenocarcinoma of Lung, Carcinoma, Neuroendocrine, Pheochromocytoma, Seminoma, Choriocarcinoma, Cystadenocarcinoma, Cystadenocarcinoma, Serous, Carcinoma, Endometrioid, Paraganglioma, Chordoma, Fibromatosis, Aggressive, Hemangiosarcoma, Trophoblastic Neoplasms, Adenocarcinoma, Mucinous, Gestational Trophoblastic Disease, Adenocarcinoma, Clear Cell, Nerve Sheath Neoplasms, Neurofibrosarcoma, Fibroma, Thyroid Neoplasms, Cystadenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Vulvar Neoplasms, Sex Cord-Gonadal Stromal Tumors, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Paget Disease, Extramammary, Adenocarcinoma, Papillary, Carcinoma, Acinar Cell, Adenocarcinoma, Bronchiolo-Alveolar, Mixed Tumor, Mullerian, Carcinoma, Giant Cell, Neoplasms, Unknown Primary, Neoplasms
Last Updated: April 28, 2020
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Last Updated: April 24, 2020
- Mesothelioma Doctors
- Cancer Centers
- Treatment Near You
- Experimental Treatments
- Alternative Treatments
- Clinical Trials
- Caregiver Resources
- Treatment Costs